Neoplasms

Second Systematic Review and Meta-Analysis Published Demonstrating DecisionDx-Melanoma as Independent Predictor of Recurrence, Distant Metastasis and Overall Survival in Cutaneous Melanoma

Thursday, July 9, 2020 - 1:17pm

The article titled, A Systematic Review and Meta-Analysis of Gene Expression Profiling for Primary Cutaneous Melanoma Prognosis, appeared in SKIN: The Journal of Cutaneous Medicine.

Key Points: 
  • The article titled, A Systematic Review and Meta-Analysis of Gene Expression Profiling for Primary Cutaneous Melanoma Prognosis, appeared in SKIN: The Journal of Cutaneous Medicine.
  • This is the second recently published systematic review and meta-analysis that demonstrates the independence and significance of DecisionDx-Melanoma prognosis for recurrence and metastatic risk in patients with invasive cutaneous melanoma.
  • The purpose of this systematic review and meta-analysis was to consolidate the rapidly evolving body of data on gene expression profiling (GEP) in melanoma prognosis.
  • Meta-analysis refers to the use of statistical techniques in a systematic review to integrate the results of included studies.

Ziopharm Oncology Doses First DIPG Patient in Phase 1/2 Trial of Controlled IL-12 for the Treatment of Pediatric Brain Tumors

Wednesday, July 8, 2020 - 1:30pm

BOSTON, July 08, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Ziopharm or the Company) (Nasdaq:ZIOP) today announced that the first patient with diffuse intrinsic pontine glioma (DIPG) has been dosed in its phase 1/2 study of Ad-RTS-hIL-12 with veledimex (Controlled IL-12) for the treatment of pediatric brain tumors.

Key Points: 
  • BOSTON, July 08, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Ziopharm or the Company) (Nasdaq:ZIOP) today announced that the first patient with diffuse intrinsic pontine glioma (DIPG) has been dosed in its phase 1/2 study of Ad-RTS-hIL-12 with veledimex (Controlled IL-12) for the treatment of pediatric brain tumors.
  • We are pleased to report that this young child has tolerated the dosing regimen well, said Laurence Cooper, M.D., Ph.D., Chief Executive Officer of Ziopharm.
  • For Ziopharm, this trial represents an additional clinical path for of Controlled IL-12, beyond the ongoing studies in recurrent glioblastoma (rGBM).
  • Therefore, driving T cells into this tumor could change the outcome for children with this lethal disease.

Global Lung Cancer Surgery Market: Growth, Trends and Forecasts (2020-2025) - ResearchAndMarkets.com

Wednesday, July 8, 2020 - 4:03pm

The "Lung Cancer Surgery Market - Growth, Trends, and Forecasts (2020 - 2025)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Lung Cancer Surgery Market - Growth, Trends, and Forecasts (2020 - 2025)" report has been added to ResearchAndMarkets.com's offering.
  • Rising air pollution and people getting affected by it are one of the prime factors responsible for the growth of the market for lung cancer surgery.
  • As per the American Cancer Society's estimation, the new cases of lung cancer in the United States for 2018 were around 234,030, and about 154,050 deaths were expected due to lung cancer.
  • In the United States, lung cancer survival has been improved and the incidence of localized lung cancer has increased.

Global Human Papillomavirus (HPV) Testing Markets to 2027 - The US Accounts for Over 29.5% of Global Market Size in 2020 - ResearchAndMarkets.com

Tuesday, July 7, 2020 - 10:04am

The "Human Papillomavirus (HPV) Testing - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Human Papillomavirus (HPV) Testing - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
  • Amid the COVID-19 crisis, the global market for Human Papillomavirus (HPV) Testing estimated at US$708.1 Million in the year 2020, is projected to reach a revised size of US$1.1 Billion by 2027, growing at a CAGR of 6.2% over the period 2020-2027.
  • The U.S. Accounts for Over 29.5% of Global Market Size in 2020, While China is Forecast to Grow at a 5.8% CAGR for the Period of 2020-2027
    The Human Papillomavirus (HPV) Testing market in the U.S. is estimated at US$209 Million in the year 2020.
  • The country currently accounts for a 29.51% share in the global market.

Silicon Beach-Based Nonprofit Startup Cure Glioblastoma Launches Laboratory Operations and Appoints Drs. John Boockvar and Lisa Haile as Senior Fellows

Wednesday, July 1, 2020 - 2:00pm

"Senior Fellows are more than advisors; they are integral members of the organization with a deep connection to the disease," said, Cofounder and President of Cure Glioblastoma, W. Shawn Carbonell, MD, PhD .

Key Points: 
  • "Senior Fellows are more than advisors; they are integral members of the organization with a deep connection to the disease," said, Cofounder and President of Cure Glioblastoma, W. Shawn Carbonell, MD, PhD .
  • "Cure Glioblastoma is unusual in that we are essentially a nonprofit biotech startup leading our own cutting-edge immunotherapy research programs through our newly launched laboratory operations at BioLabs LA at The Lundquist Institute .
  • Dr. Boockvar stated, "It is truly an honor to be a founding Senior Fellow of Cure Glioblastoma.
  • Cure Glioblastoma Inc. is a registered 501(c)(3) public charity operating through an entrepreneurial lean startup model to defeat brain cancer.

FDA Approves BAVENCIO as First-Line Maintenance Treatment for Patients with Locally Advanced or Metastatic Urothelial Carcinoma

Tuesday, June 30, 2020 - 11:45pm

For patients that do not progress on platinum-containing chemotherapy, BAVENCIO is administered as a first-line maintenance treatment until disease progression or unacceptable toxicity.

Key Points: 
  • For patients that do not progress on platinum-containing chemotherapy, BAVENCIO is administered as a first-line maintenance treatment until disease progression or unacceptable toxicity.
  • BAVENCIO (avelumab) is indicated in the US for the maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma (UC) that has not progressed with first-line platinum-containing chemotherapy.
  • In the US, the FDA granted accelerated approval for BAVENCIO for the treatment of adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma (MCC).
  • A fatal adverse reaction (sepsis) occurred in one (0.3%) patient with locally advanced or metastatic urothelial carcinoma (UC) receiving BAVENCIOplus best supportive care (BSC) as first-line maintenance treatment.

Aileron Therapeutics Initiates Enrollment in Schedule Optimization Part of Phase 1b/2 Study of ALRN-6924 as a Chemoprotection Agent in Small Cell Lung Cancer (SCLC) Patients Being Treated with Topotecan

Monday, June 29, 2020 - 1:30pm

Patients in this open-label trial have p53-mutated extensive disease small cell lung cancer (SCLC) and are being treated with second-line topotecan following administration of ALRN-6924.

Key Points: 
  • Patients in this open-label trial have p53-mutated extensive disease small cell lung cancer (SCLC) and are being treated with second-line topotecan following administration of ALRN-6924.
  • Dr. Aivado explained, Chemotherapy remains a critical cornerstone treatment for millions of cancer patients.
  • We treat healthy cells ahead of chemotherapy to prevent those toxicities, importantly, without interrupting chemotherapys potent onslaught against cancer cells.
  • There are two parts to the Phase 1b study: (i) dose optimization and (ii) schedule optimization.

Aspira Women’s Health, Inc. Announces First Patient Enrolled in Prospective OVANex Study for Benign Pelvic Mass Monitoring

Monday, June 29, 2020 - 1:00pm

AUSTIN, Texas, June 29, 2020 (GLOBE NEWSWIRE) -- Aspira Womens Health, Inc. (Nasdaq: AWH), a bioanalytical-based womens health company, today announced the first patient enrolled in a national clinical study of benign pelvic mass management.

Key Points: 
  • AUSTIN, Texas, June 29, 2020 (GLOBE NEWSWIRE) -- Aspira Womens Health, Inc. (Nasdaq: AWH), a bioanalytical-based womens health company, today announced the first patient enrolled in a national clinical study of benign pelvic mass management.
  • The study will enroll over 1,000 women for assessing ovarian cancer risk in women who have an adnexal mass and a high probability for developing the disease.
  • Many women who develop pelvic masses are hesitant to have surgery for a variety of reasons, clinical and personal, said Charles Dunton, MD, Global Medical Director, Aspira Womens Health (AWH).
  • With over 10 years of expertise in ovarian cancer risk assessment, ASPIRA is delivering a portfolio of pelvic mass products over a patients lifetime with our cutting-edge research.

Immutep Completes Recruitment for Part A of Phase II TACTI-002 Study

Monday, June 29, 2020 - 1:00pm

The Company expects to report more mature data from TACTI-002 in H2 CY20.

Key Points: 
  • The Company expects to report more mature data from TACTI-002 in H2 CY20.
  • In total 81 patients out of up to 109 (74%) are already enrolled in the trial at 12 clinical sites across Australia, Europe, the UK and US.
  • Recruitment is ongoing for Part B (second line NSCLC) and for stage 2 of Part C (2nd line HNSCC).
  • Current recruitment numbers for each Part are below.

2020 AACR | AnchorDx Unveiled A New Generation of Methylation Sequencing Technology, Aurora, towards the Development of A $100 Multi-Cancer Screening Test

Thursday, June 25, 2020 - 12:00pm

This one-tube DNA methylation test provides a very practical and accessible solution for routine clinical applications.

Key Points: 
  • This one-tube DNA methylation test provides a very practical and accessible solution for routine clinical applications.
  • In addition, the test offers high sensitivity and specificity, short turn-around time and low cost.
  • A key advantage of the Aurora test comes from its novel and streamlined target enrichment and sequencing library preparation strategy, resulting in significantly increased sensitivity and specificity of detecting low-abundant ctDNA methylation signals.
  • This novel technology may lead to the development of a clinically feasible, $100 multi-cancer screening test in the near future.